Oncology Company's Retrospective Ovarian Cancer Study Yields Compelling Results

Predictive Oncology Inc. (NASDAQ: POAI), recognized for its advancements in AI-driven drug discovery and biologics, has recently announced its strategic entry into the biomarker discovery market. This expansion leverages the company's AI/ML-driven platform, which has shown promise in predicting patient outcomes and drug responses in oncology. The move follows compelling results from a retrospective ovarian cancer study conducted with UPMC Magee-Womens Hospital. $Predictive Oncology(POAI.US)$